(S (S (VP (VBG Predicting) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (DT a) (JJ specific) (NN cancer))) (PP (TO to) (NP (DT a) (NN therapy)))))) (VP (VBZ is) (NP (NP (DT a) (JJ major) (NN goal)) (PP (IN in) (NP (JJ modern) (NN oncology))) (SBAR (WHNP (WDT that)) (S (VP (MD should) (ADVP (RB ultimately)) (VP (VB lead) (PP (TO to) (NP (DT a) (JJ personalised) (NN treatment))))))))) (. .))
(S (NP (NP (NNP High-throughput) (NNS screenings)) (PP (IN of) (NP (ADJP (RB potentially) (JJ active)) (NNS compounds))) (PP (IN against) (NP (NP (DT a) (NN panel)) (PP (IN of) (NP (ADJP (RB genomically) (JJ heterogeneous)) (NN cancer) (NN cell) (NNS lines)))))) (VP (VBP have) (VP (VBN unveiled) (NP (NP (JJ multiple) (NNS relationships)) (PP (IN between) (NP (NP (JJ genomic) (NNS alterations)) (CC and) (NP (NN drug) (NNS responses))))))) (. .))
(S (NP (JJ Various) (JJ computational) (NNS approaches)) (VP (VBP have) (VP (VBN been) (VP (VBN proposed) (S (VP (TO to) (VP (VB predict) (NP (NN sensitivity)) (PP (VBN based) (PP (IN on) (NP (JJ genomic) (NNS features))))))) (, ,) (SBAR (IN while) (S (NP (NNS others)) (VP (VBP have) (VP (VBN used) (NP (NP (DT the) (NN chemical) (NNS properties)) (PP (IN of) (NP (DT the) (NNS drugs)))) (S (VP (TO to) (VP (VB ascertain) (NP (PRP$ their) (NN effect)))))))))))) (. .))
(S (PP (IN In) (NP (DT an) (NN effort) (S (VP (TO to) (VP (VB integrate) (NP (DT these) (JJ complementary) (NNS approaches))))))) (, ,) (NP (PRP we)) (VP (VBD developed) (NP (NP (NN machine) (NN learning) (NNS models)) (SBAR (S (VP (TO to) (VP (VB predict) (NP (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NN cancer) (NN cell) (NNS lines))) (PP (TO to) (NP (NN drug) (NN treatment)))) (, ,) (VP (VBD quantified) (PP (IN through) (NP (NNP IC50) (NNS values)))) (, ,)) (PP (VBN based) (PP (IN on) (NP (DT both) (NP (NP (DT the) (JJ genomic) (NNS features)) (PP (IN of) (NP (DT the) (NN cell) (NNS lines)))) (CC and) (NP (NP (DT the) (NN chemical) (NNS properties)) (PP (IN of) (NP (DT the) (VBN considered) (NNS drugs))))))))))))) (. .))
(S (NP (NNS Models)) (VP (VBN predicted) (NP (NNP IC50) (NNS values)) (PP (IN in) (NP (NP (DT a) (JJ 8-fold) (NN cross-validation)) (CC and) (NP (DT an) (JJ independent) (NN blind) (NN test)))) (PP (IN with) (NP (NP (NP (NN coefficient)) (PP (IN of) (NP (NN determination))) (NNP R2)) (PP (IN of) (NP (NP (CD 0.72) (CC and) (CD 0.64)) (ADVP (RB respectively))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP (NNS models)) (VP (VBD were) (ADJP (JJ able) (S (VP (TO to) (VP (VB predict) (PP (IN with) (NP (NP (JJ comparable) (NN accuracy)) (PRN (-LRB- -LRB-) (NP (NP (NNP R2)) (PP (IN of) (NP (CD 0.61)))) (-RRB- -RRB-)))) (NP (NP (NNP IC50s)) (PP (IN of) (NP (NP (NN cell) (NNS lines)) (PP (IN from) (NP (NP (DT a) (NN tissue)) (VP (RB not) (VBN used) (PP (IN in) (NP (DT the) (NN training) (NN stage)))))))))))))) (. .))
(S (NP (PRP$ Our) (ADJP (IN in) (NN silico)) (NNS models)) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB optimise) (NP (NP (DT the) (JJ experimental) (NN design)) (PP (IN of) (NP (JJ drug-cell) (NNS screenings)))) (PP (IN by) (S (VP (VP (VBG estimating) (NP (NP (DT a) (JJ large) (NN proportion)) (PP (IN of) (NP (VBG missing) (NNP IC50) (NNS values))))) (CONJP (RB rather) (IN than)) (VP (ADVP (RB experimentally)) (VB measure) (NP (PRP them)))))))))))) (. .))
(S (S (NP (NP (DT The) (NNS implications)) (PP (IN of) (NP (PRP$ our) (NNS results)))) (VP (VB go) (PP (IN beyond) (NP (JJ virtual) (NN drug) (VBG screening) (NN design))))) (: :) (S (ADVP (RB potentially)) (NP (NP (NNS thousands)) (PP (IN of) (NP (NNS drugs)))) (VP (MD could) (VP (VB be) (VP (VBN probed) (PP (IN in) (NP (NN silico))) (S (VP (TO to) (VP (ADVP (RB systematically)) (VB test) (NP (NP (PRP$ their) (JJ potential) (NN efficacy)) (PP (IN as) (NP (JJ anti-tumour) (NNS agents)))) (PP (VBN based) (PP (IN on) (NP (PRP$ their) (NN structure))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG providing) (NP (NP (DT a) (JJ computational) (NN framework)) (SBAR (S (VP (TO to) (VP (VP (VB identify) (NP (JJ new) (NN drug) (VBG repositioning) (NNS opportunities))) (CONJP (RB as) (RB well) (IN as)) (VP (ADVP (RB ultimately)) (VB be) (ADJP (JJ useful) (PP (IN for) (NP (JJ personalized) (NN medicine)))) (PP (IN by) (S (VP (VBG linking) (NP (NP (DT the) (JJ genomic) (NNS traits)) (PP (IN of) (NP (NNS patients)))) (PP (TO to) (NP (NN drug) (NN sensitivity)))))))))))))))))) (. .))
